TALLAHASSEE, Fla. -- During an interview in Florida State coach Jimbo Fisher's office on National Signing Day in February, Fisher's cell phone wouldn't stop ringing. On a day when the Seminoles landed one of the nation's top classes, the persistent caller wasn't a recruit. As the phone kept ringing, Fisher excused himself and answered.
In 1996, when she was 4 years old, Catherine MacLean learned she had aplastic anemia. For seven years, she lived from hospital visit to hospital visit, one transfusion to the next. It wasn't until the summer of 2002 that her world suddenly included what was possible beyond the walls of her illness. She was 11.
I began taking an iron supplement because I thought I might have a case of running-induced anemia. It seemed to help, but now I wonder if I should continue taking the supplement or let it go. Am I getting too much iron?
A coroner's investigator dismissed online speculation that the pneumonia deaths of actress Brittany Murphy and her husband, Simon Monjack, may both have been related to viral mold inside their Los Angeles home.
Simon Monjack's death two months ago was caused by acute pneumonia and severe anemia, according to a Los Angeles County coroner spokesman.
Shares of Amgen and Johnson & Johnson took a hit Wednesday after a study showed their anti-anemia drugs increase the risk of blood clots and death in cancer patients. But the companies say it's old news.
Biotech Amgen on Thursday reported an increase in earnings and a decrease in sales for the fourth quarter, beating Wall Street's forecast.
CNN's Alina Cho talks with WCVB reporter Kelley Tuthill, who is chronicling her battle with breast cancer.
Amgen, the nation's second-largest biotech, was once considered immune from the chronic problems facing old-line drugmakers. But these days Amgen has all the major symptoms of "Big Pharma disease:" regulatory run-ins, price competition from generic drugs, and a virtually empty pipeline of future medicines.
Amgen reported a significant boost to second-quarter earnings Thursday after taking a large acquisition-related charge last year.
Amgen, king of the biotechs, sits on a shaky throne.
A Senate panel voted Wednesday to set a path for generic drugmakers to seek approval of cheaper, copycat versions of expensive biotechnology medicines.
In the late 1960s, Don McLean penned the nostalgic anthem "American Pie" in part to respond to what he saw as the beginning of a dark era for the U.S. Similarly, in May of this year, Lazard Capital...
CNNMoney: Stocks bounce backupdated: Fri May 11 2007 10:19:00
Stocks jumped Friday morning, recovering some of the previous session's losses thanks to reports showing moderate economic growth and mild inflationary pressures.
Lawmakers are pushing forward with legislation that could help create generic competition for Big Biotech, drastically lowering the costs of expensive biotech drugs and changing the landscape in the pharmaceutical industry forever.
The biotech Amgen reported first-quarter earnings Monday that matched expectations, though its revenue fell just short of forecasts.
Some of the most successful blockbuster drugs in the world treat diseases that most people have never heard of.
Federal health officials have issued stern new warnings for doctors to more carefully prescribe widely used anemia drugs that can increase the risk of death and other serious problems in patients with cancer and kidney disease.
Amgen's stock price tumbled Thursday, as investors grew concerned over federal scrutiny and safety issues concerning the biotech's top-selling anemia drugs.
A surge in Amgen Inc's fourth-quarter earnings fell short of analyst projections, but the company's sales topped expectations.
Biotechs didn't do so well in 2006, but analysts are expecting a strong recovery for 2007, particularly for Big Biotech.
Amgen Inc. reported a surge in third-quarter earnings, beating Wall Street's forecast.
A huge new industry - biogenerics - is waiting to be born.
Amgen and Genentech stock prices soared in 2005, but they lost their hot stock status in '06 as prices plunged. Is Big Biotech ready for an upswing, or is it all downhill from here?
Amgen Inc., the world's biggest biotech developer, beat earnings expectations for the first quarter Tuesday, but analysts were still skeptical about the company's performance.
Drug sales, bolstered by Medicare coverage, are projected to keep rising for the next 10 years, and biotechs are expected to get the lion's share of that increase, while the more traditional Big Pharma companies get squeezed by generic drug makers.
Amgen's stock price climbed for a second consecutive day after the biotech and its partner Abgenix unveiled new data for an anti-cancer antibody.
Johnson & Johnson has reportedly filed an antitrust suit charging that biotech company Amgen illegally drove J&J's drug Procrit out of the market using illegal market leverage.
The Empire State ballroom at the Grand Hyatt Hotel in midtown Manhattan typically serves as the setting for the kind of stuffy, state-of-a-business luncheons that are more snooze inducing than buzz...
Nokia's disappointing sales announcement and the resulting fallout in the tech sector makes a lot of nervous investors even jumpier. In particular, they fear that any earnings disappointments during the next few weeks may lead to sudden selloffs.
Lee Hood: the man who automated biology
Fortune: The Next Biohazardupdated: Mon Sep 02 2002 00:01:00
Johnson & Johnson stock got hammered in mid-July when the government launched an investigation into its plant in Puerto Rico that makes Eprex, a bioengineered medicine sold outside the U.S. to trea...
When we last wrote about biotech stocks back in May 2000, we warned that they have a gut-wrenching "tendency to boom, then bust." Sure enough, the sector has since plunged, soared, then plunged aga...
Once again, the tech stocks in the MONEY 30 were seriously slammed by Wall Street. Indeed, three companies--Cisco, Oracle and Sun Microsystems--each lost more than 25% of their value in the month e...
The MONEY 30, an index of blue-chip growth stocks at the forefront of today's economy, rose just 0.3%--to 4293--from Aug. 15 to Sept. 8 (January 1996 = 1000). Biotech giant Amgen was the best perfo...
As soon as the next few weeks, Judge William Young could issue a ruling from his crowded Boston courtroom in what is probably the most closely watched biotech battle ever. The issues the trial rais...
SIGNS OF HYPERGROWTH are everywhere at Amgen, the Thousand Oaks, California, biotechnology firm. Like an amoeba, the company, which already sprawls over 17 low-slung buildings, is fast engulfing it...
© 2013 Cable News Network. Turner Broadcasting System, Inc. All Rights Reserved.
|